Physician profile
Michael Beard
NPI 1316949167
$8,891.30
in general payments reported to CMS, 2019-2025
40 companies · $884 in 2025
The $884 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $712 · 2021: $1,860 · 2022: $1,697 · 2023: $1,703 · 2024: $816 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $810.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $810.26 | 2019-2024 | Repatha, Otezla, Aimovig |
| Astrazeneca Pharmaceuticals Lp | $803.47 | 2019-2025 | Brilinta, Farxiga, Airsupra |
| Pfizer INC. | $739.50 | 2019-2025 | |
| Abbvie INC. | $715.78 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $411.80 | 2019-2024 | Mounjaro, Emgality, Reyvow |
| Abbott Laboratories | $378.47 | 2021-2024 | Freestyle Libre 3, Amplatzer Amulet |
| Allergan, INC. | $364.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $358.05 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $344.05 | 2020-2021 | |
| Amarin Pharma, INC. | $327.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.14 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $241.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $224.03 | 2019-2023 | Belsomra, Verquvo |
| Supernus Pharmaceuticals, INC. | $216.04 | 2019-2021 | Tlando, Xyosted |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.